Direct Oral Anticoagulant Edoxaban in Patients with Non-Valvular Atrial Fibrillation: Results of Direct Comparison with Warfarin

This review analyzes results of a large prospective, randomized, double-blind, placebo-controlled clinical study ENGAGE AF-TIMI 48 that compared efficacy and safety of warfarin, a vitamin K antagonist, and edoxaban, an oral inhibitor of activated coagulation factor X. The review addresses important...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Kardiologiia 2020-09, Vol.60 (8), p.124-129
1. Verfasser:	Yavelov, I S
Format:	Artikel
Sprache:	eng ; rus
Schlagworte:	Administration, Oral Anticoagulants - therapeutic use Atrial Fibrillation - complications Atrial Fibrillation - drug therapy Double-Blind Method Factor Xa Inhibitors - therapeutic use Humans Prospective Studies Pyridines Randomized Controlled Trials as Topic Stroke - drug therapy Thiazoles Treatment Outcome Warfarin - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	This review analyzes results of a large prospective, randomized, double-blind, placebo-controlled clinical study ENGAGE AF-TIMI 48 that compared efficacy and safety of warfarin, a vitamin K antagonist, and edoxaban, an oral inhibitor of activated coagulation factor X. The review addresses important practical aspects of using edoxaban in patients with nonvalvular atrial fibrillation.
ISSN:	0022-9040 2412-5660
DOI:	10.18087/cardio.2020.8.n1244